EUCTR2017-002871-24-BE进行中（未招募）1 期
A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in patients with clinical recent-onset Type 1 Diabetes Mellitus (T1D)
Intrexon T1D Partners, LLC (IT1D)0 个研究点目标入组 48 人开始时间: 2018年5月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or non-pregnant, non-lactating females, 18-40 years of age (both inclusive) or 12-17 years of age (both inclusive)
- •- Diagnosis of diabetes according to the ADA recommended criteria
- •- Evidence of auto-antibodies to at least 1 of the following ß-cell autoantigens: insulin, IA-2, GAD65, ZnT8
- •- Stimulated C-peptide measured during 4h Mixed Meal tolerance Test (MMTT) > 0.2 nmol/L
- •- The first administration of AG019 should occur no later than 150 days post diagnosis
- •- Body weight = 33kg
- •- Willing and medically able to postpone live vaccine immunizations for at least 8 weeks after randomization
- •- Ability and willingness of patients to participate fully in all aspects of this clinical study
- •- Written informed consent obtained and documented
- •- Willingness to use a continuous glucose monitoring device and willingness to comply with the protocol defined glucose monitoring
- •- Total bilirubin =1.0 x upper limit of normal (ULN), Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =1.5 x ULN, =1,000 lymphocytes/µL, =1,000 polymorphonuclear neutrophils (PMN)/µL, =100,000 platelets/µL, Hgb =10 g/dL, Serum Creatinin =1.5 x ULN, eGFR =60 mL/min/1.73m², INR =0.1 above upper limit of normal, Absence of clinically significant age appropriate abnormalities on all other lab values, except for abnormalities directly attributable to T1D
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 24
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Previous history of serious cytokine release syndrome to teplizumab or other humanized anti-CD3 monoclonal antibodies with no or minimal capacity to bind Fc receptors
- •- Current use of any systemic antibiotics, except for the following: metronidazole (metronidazole), nalidixic acid (first generation quinolone), trimethoprim, sulfamethoxazole (sulfonamide) and/or a combination of both in a ratio 1/19 (sulfonamides)
- •- Use of immunosuppressive or immunomodulatory therapies, including systemic steroids within 1 month prior to randomization
- •- Participation in another investigational drug trial within 12 weeks prior to the first study drug intake and during participation in this study
- •- History of recurrent infections, other autoimmune diseases, cardiac disease, malignancy, or any other (chronic) medical condition which, in the investigator’s opinion, could compromise participant safety
- •- Documented history of human immunodeficiency virus (HIV), Hepatitis Virus Type C (HCV), Hepatitis Virus Type B (HBV) infection
- •- Evidence of active infection with Epstein-Barr Virus (EBV) or cytomegalovirus (CMV)
- •- Untreated hypothyroidism or active Graves’ disease
- •- Evidence of any active infection with the exception of superficial skin infections
- •- Vaccination with live virus or organism within 8 weeks prior to randomization
- •- Evidence of active or latent tuberculosis (TB)
- •- Administration of anti-CD3 antibody in past year
- •- Current therapy with any other anti-diabetic agents other than insulin (MDI, CSII or analogue). Current or planned therapy with experimental (i.e., unapproved) insulin
- •- Use of medications known to influence glucose tolerance
- •- Daily use of non-steroidal anti-inflammatory agents
- •- Compromised GI mucosal integrity or motility, not attributable to T1D (i.e., recent diarrhea, gluten sensitive enteropathy, inflammatory bowel disease, irritable bowel syndrome), or current use of medications known to influence GI motility
- •- Inability to swallow size 1 capsules
- •- Alcohol or illicit drug consumption, which in the opinion of the investigator, may interfere with the patient’s ability to comply with the study procedures
- •- Active psychiatric problems, which in the opinion of the investigator, may interfere with the patient’s ability to comply with study procedures
研究者
相似试验
已完成
2 期
A prospective, multicenter, Phase II study to evaluate the safety and efficacy of eculizumab in subjects with Guillain-Barre syndromeGuillan-Barre syndromeJPRN-UMIN000018171Chiba University, Graduate School of Medicine Department of Neurology33
招募中
2 期
Clinical Trial of Cefepime-Zidebactam (FEP-ZID) for the Treatment of Adult Subjects with Serious bacterial InfectionsCTRI/2024/04/065043Ms Wockhardt Limited
招募中
1 期
Tuvusertib (M1774) in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322)on-Squamous Non-Small Cell Lung CancerCTIS2022-502010-85-00Merck Healthcare KGaA198
进行中（未招募）
1 期
Study of ART6043 in Advanced/?Metastatic Solid Tumors PatientsCTIS2023-509220-17-00Artios Pharma Limited120
终止
2 期
A phase II/III study to evaluate the efficacy and safety of MD 920 (Gibberellic Acid and Salt 1:1) in patients with hard to heal chronic venous ulceratioACTRN12608000060347AUS BIO Ltd158